Veterinary Monoclonal Antibodies Market worth $3.06 billion by 2030
The report "Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030", is expected to reach USD 3.06 billion by 2030, from USD 1.70 billion in 2025, with a CAGR of 12.4%.
Browse 230 market data Tables and 54 Figures spread through 253 Pages and in-depth TOC on "Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/veterinary-monoclonal-antibodies-market-250696769.html
The veterinary monoclonal antibodies market is growing steadily due to rising rates of chronic diseases in animals and increasing pet ownership. Conditions like atopic dermatitis and osteoarthritis pain are common among companion animals. To treat these conditions, the market offers a range of approved products, such as Cytopoint, Librela, Solensia, Gilvetmab, and Canine Parvovirus Monoclonal Antibody (CPMA), which have gained significant traction, thereby fueling market growth. Additionally, advances in technology, including new biologic therapeutics, improved diagnostics, and teledermatology, are enhancing treatment outcomes. Growing awareness, pet insurance coverage, and increased R&D spending are also shaping the market, driving innovation and expanding treatment options.
“By animal type, canine is expected to be the fastest-growing segment during the forecast period.”
The canine segment is expected to experience the fastest growth rate. Key factors driving this segment include the rising adoption of pets, increasing spending on pet health, and growing concerns about skin conditions in dogs. Furthermore, there is a growing demand among pet owners worldwide for advanced monoclonal antibody therapies.
“By therapy area, dermatology accounted for the largest market share in 2024.”
The dermatology segment accounted for the largest market share in 2024. Common chronic conditions in companion animals, such as allergic dermatitis and atopic dermatitis, drive this trend. The increasing awareness of animal health, along with the availability of advanced monoclonal antibody therapies for treating these diseases, also contributes to the overall growth of the market.
“Asia Pacific is expected to witness significant growth during the forecast period.”
Asia Pacific’s rapid market expansion is attributed to the rising pet population, increasing awareness about animal skin diseases, and growing expenditure on veterinary care. Advanced veterinary healthcare infrastructure and the presence of key market players are further driving growth in countries like China, India, and Japan. Livestock farming also plays a significant role in the region’s economy. India and China have a large number of livestock animals, driven by the high demand for meat, milk, and other animal-based products.
Key Market Players
Prominent players in the veterinary monoclonal antibodies market are Zoetis Services LLC (US), Elanco (US), and Merck & Co., Inc. (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Veterinary Monoclonal Antibodies Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
